Emergence of drug-resistant Elizabethkingia anophelis clinical isolates in Myanmar.

Seven drug-resistant Elizabethkingia anophelis isolates were obtained from inpatients in three medical settings in Myanmar between February 2017 and January 2021. All isolates were resistant to β-lactams and colistin. Among these, four isolates were resistant to amikacin with minimum inhibitory concentration (MIC) of ≥64 µg ml-1. Six of the seven isolates harboured genes encoding intrinsic β-lactamases, including bla B, bla CME and bla GOB, whereas one isolate harboured bla B, bla CME and an incomplete bla GOB gene. Phylogenetic analysis based on whole-genome sequences revealed that several E. anophelis isolates in Myanmar formed their own clusters, whereas others were similar to isolates found in the USA. This is the first report of the emergence of Elizabethkingia species in Myanmar.